Monday, October 18, 2021
News

Drug companies eye mRNA technology for flu shots

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

London | Thursday, 2021 10:45:05 PM IST
With Covid-19 proving the credibility of mRNA technology, many drug companies are racing to apply the same formula for developing vaccines for influenza, Nature reported.

While Moderna, Pfizer and Sanofi have, in recent months, initiated Phase 1 trials of mRNA-based seasonal flu vaccine candidates, more companies intend to follow their leads next year.

However, unlike Covid-19, mRNA-based flu shots could also prove a more challenging test as nine flu jabs from four different vaccine manufacturers are already available in the US alone.

Although the shots built around inactivated viruses or recombinant proteins are safe, they typically offer only 40-60 per cent protection from infection.

At the same time, mRNA-based jabs might produce broader immune responses, better sequence fidelity of proteins, and accurate strain selection. Moreover, the technology makes it easy to incorporate large numbers of antigens -- all of which could translate into greater immune protection, the report said.

But mRNA is also prone to tolerability issues, as seen in Covid shots developed by Moderna and Pfizer -- they often cause sore arms, headaches, low-grade fevers and fatigue. These same symptoms can occur with approved flu shots, but typically are much milder in degree.

On the other hand, the potential benefits of mRNA for preventing flu are many, majorly because of how it is manufactured.

"Because mRNA vaccines are manufactured synthetically, by encoding a target antigen sequence into a plasmid template, they offer high fidelity: encoded antigens exactly match the flu strains selected for each year's vaccine. By contrast, inactivated virus vaccines that are made in egg- and cell-based systems often suffer from sequence mutations that weaken their effectiveness," the report said.

The recombinant protein vaccines also offer that same fidelity advantage, but the manufacturing process for these is comparatively cumbersome.

The flexibility and speed of mRNA vaccine production also means that drug makers could wait longer to begin manufacturing -- starting production in May, say, instead of February, for the northern hemisphere. This would enable them to make more informed decisions about what strains to include, the report said.

--IANS rvt/vd

( 350 Words)

2021-10-14-16:34:04 (IANS)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
K'taka lifts curbs at MM Hills pilgrimag...
Dasara beats Covid fears, boosts tourism...
What made Delta, Delta Plus variants of ...
Statins may reduce risk of death from Co...
Slip disc, sciatica can be treated with ...
Ranking healthfulness of foods from firs...
More...
 
INDIA WORLD ASIA
Babul Supriyo to submit resignation as B...
Flood-affected Kerala to witness rains f...
2 labourers from Bihar killed, another i...
Eyeing 2023 polls, tribal parties revive...
Mob forces Bhopal woman to remove burqa,...
Ensuring prosperity in life of every nee...
More...    
 
 Top Stories
Imran Khan trying to turn ISI into ... 
K'taka lifts curbs at MM Hills pilg... 
Flood-affected Kerala to witness ra... 
5.0 magnitude quake hits Severo-Kur... 
2 labourers from Bihar killed, anot... 
K'taka Minister in UAE makes strong... 
Ethiopian, Kenyan runners win Amste... 
Communicating with the eyes is a be...